Scientific Publications Disclaimer

These publications include discussions of unapproved uses that have not been approved by FDA. The safety and effectiveness of the medical product for the unapproved use has not been established. Users are encouraged to review the full labeling for the product, as well as all disclosures about the individual publications.


Summary

  • The Evolut™ platform was designed and approved for use in symptomatic patients with severe native calcific aortic stenosis (AS), when a heart team (including a cardiac surgeon) judges them appropriate for transcatheter heart valve replacement. For patients with symptomatic failure of a surgical or transcatheter bioprosthetic aortic valve at high or greater risk for surgery by a heart team, based on a predicted 30-day surgical mortality risk ≥ 8%.
  • The Evolut™ platform is not currently approved for the treatment of patients with moderate aortic stenosis. The articles provided are intended to describe the natural history and progression of aortic stenosis, including discussion of the scientific rationale for investigating earlier aortic valve intervention. Inclusion of these articles does not establish the safety or effectiveness of the Evolut™ platform for moderate aortic stenosis or imply an approved indication or endorsement of this use.


Contact us

Office of Medical Affairs
Garrett Nintzel, PA-C
Phone: 877-526-7890


Articles of interest

Medtronic summary

  • State-of-the-art review of moderate AS diagnosis, multimodality imaging, risk stratification, and management
  • Emphasizes accurate AS severity assessment, particularly with discordant valve area, gradient, or flow measurements, and the role of multimodality imaging in evaluating ventricular remodeling
  • Reviews evidence associating moderate AS with adverse cardiovascular outcomes and discusses the interaction between valve obstruction, ventricular function, and arterial vasculature
  • Emerging evidence associates moderate AS with reduced survival, highlighting the importance of assessing ventricular remodeling and identifying higher-risk patients
  • Randomized trials are needed to determine whether earlier transcatheter aortic valve replacement improves clinical outcomes in moderate aortic stenosis patients


Stassen J, Ewe SH, Pio SM, et al. Managing patients with moderate aortic stenosis. JACC Cardiovasc Imaging. 2023;16(6):837–855. doi:10.1016/j.jcmg.2022.12.013.

Disclosures: Dr. Pibarot reports research funding and speaker fees from Medtronic. Dr. Leipsic reports institutional core laboratory grants from Medtronic. Dr. Généreux reports consultant/advisor and speaker fees from Medtronic. Dr. Van Mieghem reports research grants from Medtronic. Dr. Makkar reports consulting and research grants from Medtronic. Dr. Hahn reports institutional consulting for Medtronic. Dr. Delgado reports speaker fees from Medtronic. Dr. Leon reports institutional clinical research grants from Medtronic. The remaining authors have no disclosures.

Medtronic summary

  • Retrospective single-center study of 688 patients with moderate AS; median follow-up of 3.6 years
  • Advanced cardiac damage (stages 3–4) was associated with higher risk of all-cause death or heart failure hospitalization (adjusted HR 3.40; 95% CI 1.59–7.26)
  • Aortic valve replacement (AVR) was performed in 196 patients, most commonly following progression to severe symptomatic AS. Cardiac damage accumulated while awaiting AVR and partially recovered afterward.
  • Increasing cardiac damage in patients with moderate AS is associated with worse clinical outcomes and may not fully reverse following AVR. Further studies are needed to determine which patients may benefit from earlier intervention.
  • Limitations include selection/residual confounding, a small advanced-stage subgroup, descriptive transition analyses, missing follow-up, and the absence of a comparable untreated group for the before/after AVR analysis


Harmon EK, Howard T, Tereshchenko LG, et al. Cardiac damage staging, moderate aortic stenosis, and the impact of aortic valve replacement. JACC Adv. 2025;4(12 pt 2):102348. doi:10.1016/j.jacadv.2025.102348.

Disclosures: The authors report no disclosures.

Medtronic summary

  • Systematic review and meta-analysis of 25 observational studies involving 12,143 patients with moderate AS
  • Pooled all-cause mortality was 9.0 deaths per 100 person-years (95% CI 6.9–11.7), higher than no/mild AS but lower than severe AS
  • Moderate AS is associated with a higher mortality risk than no or mild AS, particularly among patients with high-risk features. Further studies are needed to determine whether earlier aortic valve replacement improves outcomes in these patients.
  • Limitations include varying AS definitions, possible low-flow/low-gradient severe AS misclassification, and unadjusted comparisons across AS grades. Generalizability is impacted, but still the descriptive disease-burden conclusion stands.


Coisne A, Scotti A, Latib A, et al. Impact of moderate aortic stenosis on long-term clinical outcomes: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2022;15(16):1664–1674. doi:10.1016/j.jcin.2022.06.022.

Disclosures: Dr. Latib reports having served on advisory boards or as a consultant for Medtronic. Dr. Généreux reports serving as a consultant for Medtronic.


Considerations 

Indications

The Medtronic Evolut™ PRO+, Evolut™ FX, and Evolut™ FX+ Systems are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be appropriate for the transcatheter heart valve replacement therapy.

The Medtronic Evolut PRO+, Evolut FX, and Evolut FX+ Systems are indicated for use in patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical or transcatheter bioprosthetic aortic valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Contraindications

The Medtronic Evolut PRO+, Evolut FX, and Evolut FX+ Systems are contraindicated in patients who cannot tolerate Nitinol (titanium or nickel), gold (for Evolut FX and Evolut FX+ Systems alone), an anticoagulation/antiplatelet regimen, or who have active bacterial endocarditis or other active infections.

Warning and precautions

General Implantation of the Evolut PRO+, Evolut FX, and Evolut FX+ Systems should be performed only by physicians who have received Medtronic Evolut PRO+, Evolut FX, or Evolut FX+ training. This procedure should only be performed where emergency aortic valve surgery can be performed promptly. Mechanical failure of the delivery catheter system and/or accessories may result in patient complications. Transcatheter aortic valve (bioprosthesis) Accelerated deterioration due to calcific degeneration of the bioprostheses may occur in: children, adolescents, or young adults; patients with altered calcium metabolism (e.g., chronic renal failure or hyperthyroidism).

Precautions

General Clinical long-term durability has not been established for the bioprosthesis. Evaluate bioprosthesis performance as needed during patient follow-up. The safety and effectiveness of the Evolut PRO+, Evolut FX, and Evolut FX+ Systems have not been evaluated in the pediatric population. The safety and effectiveness of the bioprostheses for aortic valve replacement have not been evaluated in the following patient populations: Patients who do not meet the criteria for symptomatic severe native aortic stenosis as defined: (1) symptomatic severe high-gradient aortic stenosis — aortic valve area ≤ 1.0 cm2 or aortic valve area index ≤ 0.6 cm2/m2, a mean aortic valve gradient ≥ 40 mm Hg, or a peak aortic-jet velocity ≥ 4.0 m/s; (2) symptomatic severe low-flow, low-gradient aortic stenosis — aortic valve area ≤ 1.0 cm2 or aortic valve area index ≤ 0.6 cm2/m2, a mean aortic valve gradient < 40 mm Hg, and a peak aortic-jet velocity < 4.0 m/s.

Potential adverse events

Potential risks associated with the implantation of the Evolut PRO+, Evolut FX, or Evolut FX+ transcatheter aortic valve may include, but are not limited to, the following:

  • death
  • myocardial infarction, cardiac arrest, cardiogenic shock, or cardiac tamponade
  • coronary occlusion, obstruction, or vessel spasm (including acute coronary closure)
  • cardiovascular injury (including rupture, perforation, tissue erosion, or dissection of vessels, ascending aorta trauma, ventricle, myocardium, or valvular structures that may require intervention)
  • emergent surgical or transcatheter intervention (e.g., coronary artery bypass, heart valve replacement, valve explant, percutaneous coronary intervention [PCI], balloon valvuloplasty)
  • prosthetic valve dysfunction (regurgitation or stenosis) due to fracture; bending (out-of-round configuration) of the valve frame; underexpansion of the valve frame; calcification; pannus; leaflet wear, tear, prolapse, or retraction; poor valve coaptation; suture breaks or disruption; leaks; mal-sizing (prosthesis-patient mismatch); malposition (either too high or too low)/malplacement – prosthetic valve migration/embolization
  • prosthetic valve endocarditis
  • prosthetic valve thrombosis
  • delivery catheter system malfunction resulting in the need for additional recrossing of the aortic valve and prolonged procedural time
  • delivery catheter system component embolization
  • stroke (ischemic or hemorrhagic), transient ischemic attack (TIA), or other neurological deficits
  • individual organ (e.g., cardiac, respiratory, renal [including acute kidney failure]) or multi-organ insufficiency or failure
  • major or minor bleeding that may require transfusion or intervention (including life-threatening or disabling bleeding)
  • vascular access-related complications (e.g., dissection, perforation, pain, bleeding, hematoma, pseudoaneurysm, irreversible nerve injury, compartment syndrome, arteriovenous fistula, or stenosis)
  • mitral valve regurgitation or injury
  • conduction system disturbances (e.g., atrioventricular node block, left bundle-branch block, asystole), which may require a permanent pacemaker
  • infection (including septicemia)
  • hypotension or hypertension
  • hemolysis
  • peripheral ischemia

 

General surgical risks applicable to transcatheter aortic valve implantation:

  • bowel ischemia
  • abnormal lab values (including electrolyte imbalance)
  • allergic reaction to antiplatelet agents, contrast medium, or anesthesia
  • exposure to radiation through fluoroscopy and angiography
  • permanent disability.

Please reference the Evolut PRO+, Evolut FX, and Evolut FX+ Instructions for Use for more information regarding indications, warnings, precautions, and potential adverse events.

Caution: Federal Law (USA) restricts these devices to the sale by or on the order of a physician.

The commercial name of the Evolut™ PRO+ device is Medtronic Evolut™ PRO+ System, the commercial name of the Evolut™ FX device is Medtronic Evolut™ FX System, and the commercial name of the Evolut™ FX+ device is Medtronic Evolut™ FX+ System.